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The progression of papillomas to squamous cell carcinomas (malignant conversion) was studied in the
skin of SENCAR and Charles River CD-1 mice, using a three-stage treatment protocol. After initiation
with 7,12-dimethylbenz(a)anthracene (DMBA) (stage 1) and limited promotion by 12-0-tetradecanoyl-
phorbol-13-acetate (TPA) (stage II), papilloma-bearing mice were treated (stage III) with either tumor
initiators, such as urethane, N-methyl-N'nitro-N-nitrosoguanidine (MNNG) or 4-nitroquinoline-n-oxide
(R-NQO), the promoter TPA, or solvent (acetone). Similar final carcinoma yields were found in the mice
treated in stage III with TPA or acetone, although carcinomas developed earlier in the TPA-treated mice.
In contrast, treatment with tumor initiators in stage III increased both the rate of appearance and the
final yield of carcinomas. Similar results were obtained in both SENCAR and CD-1 mice. A papilloma
stage appears to be necessary for carcinoma development since elimination of TPA treatment in stage II
greatly reduced the incidence ofboth papillomas and carcinomas in both stocks ofmice. The heterogeneity
of papillomas with regard to progression to carcinomas is demonstrated by the low rate of conversion of
TPA-dependent papillomas and the high rate of conversion of persistent papillomas in CD-1 mice. The
carcinomas that develop using the three-stage regimen vary in metastatic potential. In CD-1 mice, the
frequency ofmetastases to lymph nodes were similar in groups treated in stage III with MNNG, urethane,
4-NQO, TPA, or acetone, but treatment with urethane substantially increased metastases to the lung. In
SENCAR mice, this effect of urethane was not observed, but lymph node and lung metastases appeared
to be increased by stage III treatment with MNNG.
Introduction
The initiation-promotion model of epidermal carcin-
ogenesis in mice has provided the basis for many con-
ceptual advances in the understanding ofthe biology of
carcinogenesis (1-3). Initiation by a single treatment
with a low dose of carcinogen such as 7 12-dimethyl-
benz(a)anthracene (DMBA) (stage I) results in the per-
manent alteration of some epidermal cells (Table 1). In
the absence of further treatment, these initiated cells
do not develop into tumors, but the cellular changes are
heritable. As a result ofsubsequent repeated exposure
ofinitiated skin topromoting agents (stage II), multiple
benign papillomas develop. The promotion process is
reversible; papillomas do not develop after insufficient
promoter treatment or if the interval between treat-
ments is prolonged. Many papillomas regress when the
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promoting stimulus is removed (4). Other papillomas
progress irreversibly to carcinomas, either sponta-
neously or as a result offurther exposure to a genotoxic
tumorinitiator; this process has been termed malignant
conversion (stage III) (5). Continuedtreatmentwiththe
tumor promoter 12-0-tetradecanoylphorbol-13-acetate
(TPA) increases the rate of malignant conversion, but
does not alter the final carcinoma incidence (5). The
factors responsible for this conversion have only been
studied recently, although Berenblum (6) recognized
the conversion ofbenign papillomas to carcinomas as a
specific stage nearly 45 years ago. Metastasis of skin
squamous cell carcinomas to the lungs and lymph nodes
occurs as a fourth stage in epidermal carcinogenesis.
The irreversibility of both initiation and malignant
conversionandthegenotoxicnatureofthe active agents
suggests that these processes involve genetic altera-
tions. The increased proliferation rate in promoter-
treated epidermis and in papillomas may increase the
probability of genetic changes necessary for the pro-
gression ofpapillomas to carcinomas (7,8). Three-stage
carcinogenesis hasbeendemonstratedonlyinSENCARHENNINGS ET AL.
Table 1. Multistage epidermal carcinogenesis.
Stage End point
I. Initiation Initiated cells
II. Promotion (stages 1 and 2) Papillomas
III. Malignant conversion Squamous cell carcinomas
IV. Metastasis Metastatic squamous cell
carcinomas
mice (5). In this report, results of further experiments
with SENCAR mice are compared to those from similar
experiments in Charles River CD-1 mice. Furthermore,
rates and sites of metastasis of squamous cell carcino-
mas are compared in the two stocks of mice.
Materials and Methods
Chemicals
7,12-Dimethylbenz(a)anthracene (DMBA) was ob-
tained from Eastman (Rochester, NY). 12-0-Tetrade-
canoylphorbol-13-acetate (TPA) was purchased from
LC Services (Woburn, MA); N-methyl-N'-nitro-N-ni-
trosoguanidine (MNNG) was purchased from Aldrich
(Milwaukee, WI); 4-nitroquinoline-N-oxide (4-NQO)
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FIGURE 1. Carcinoma incidence in three-stage carcinogenesis in
SENCAR mice. Groups of30female SENCAR mice were initiated
with 20 Iug DMBA (stage I) and treated with 10 weekly applica-
tions of either (0, A) TPA (2.0 ,ug/0.2 mL acetone)or (0, A)
acetone in stage II. Once weekly treatments with (A, A) urethane
(20 mg intraperitoneal) or (0,O) 4-NQO (250 I.g/0.2 mL acetone)
continued from weeks 11 to 40 in stage III. Suspected carcinomas
were scored biweekly and were verified by histological examina-
tion.
was purchased from Sigma (St. Louis, MO); urethane
was purchased from MCB (Cincinnati, OH).
Mice
SENCAR female mice were obtained from the NCI-
DCT Animal Program. Charles River CD-1 femalemice
were purchased from Charles River Laboratories,
Kingston, NY. Mice were shipped at 4 to 5 weeks of
age.
Tumor Induction Experiments (Three-
Stage Carcinogenesis)
Mice, 7 to 8 weeks old, were shaved before stage I
initiationwith asingle topicalapplication ofDMBA. The
DMBA dose was 20 jig in SENCAR mice and 50 ,ug in
CD-1 mice. Stage II TPA treatments began one week
after initiation. In SENCAR mice, 2 ,ug or 2.5 p,g TPA
was given weekly for 10 weeks; in CD-1 mice, 10 pug
TPA was given weekly for 12 weeks. Stage III treat-
ments with either urethane, 4-NQO, MNNG, TPA, or
acetone were begun one week afterStage II treatments
were completed. The duration of the once per week
stage III treatments was 30 weeks in SENCAR mice
and 40 weeks in CD-1 mice. All chemicals for topical
treatment were dissolved in reagent-grade acetone
(Baker, Philipsburg, NJ) and applied in a volume of0.2
mL. Specific treatment protocols are described in the
legends to figures.
Papilloma and carcinoma counts were recorded
weekly orbiweekly, and mice were weighed and shaved
carefully once per month. A lesion was counted as a
papilloma when it reached a diameter of more than 1
mm and was present for two consecutive weeks. Sus-
pected carcinomas were verified histologically. Patho-
logicalevaluation ofmostpapillomaswasnotperformed;
thus, early carcinomas arising in papillomas would not
have been detected and the carcinomaincidences shown
may underestimate the actual incidence.
Results and Discussion
Malignant Conversion in SENCAR mice
In tumor induction experiments in Swiss mice, most
squamous cell carcinomas progress from papillomas
(9,10), but the rate of conversion is low. The factors
necessary for this malignant conversion have not been
defined. After DMBA initiation (stage I) and limited
TPA promotion (stage II) in SENCAR mice, continued
TPA treatment of these papilloma-bearing mice was
compared to repeated exposure to an initiator for the
effect on carcinoma development (stage III). Exposure
to the promoter TPA in stage III does not influence the
final carcinoma yield, but the treatment of papilloma-
bearing mice with genotoxic tumor initiators markedly
accelerates and enhances malignant conversion. The
carcinomaincidencewasincreasedsignificantlybystage
III treatments with 4-NQO, MNNG, and urethane for
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FIGURE 2. Papilloma and carcinoma incidence in a three-stage carcinogenesis experiment in CD-1 mice. Groups of 40 female CD-1 mice
were initiated with 50 ,ug DMBA (stage I) and promoted with 12 weekly applications of 10 ,ug TPA (stage II). The indicated stage III
treatments once weekly from weeks 13 to 52 were as follows: (D) acetone, 0.2 mL; (U) TPA, 10 ,ug; (A) urethane, 20 mg IP; (0) 4-NQO,
250 Vt.
30 weeks (5). Control groups ofSENCAR mice treated
only with the active stage III agents showed that ur-
ethane induced no tumors, 4-NQO induced few papil-
lomas and no carcinomas, while MNNG was moderately
active as a complete carcinogen (5).
Whenthisexperiment wasrepeated, stage III4-NQO
or urethane treatment ofpapilloma-bearing mice for 30
weeks again induced carcinomas in more than half the
mice within 30weeks (Fig. 1). Incontrol groups treated
with acetone rather than TPA in stage II, stage III
treatment with 4-NQO or urethane induced few carci-
nomas (Fig. 1). These carcinomas appeared 20 weeks
or more later than those in mice treated with TPA in
stage II. In contrast, with MNNG in stage III, a high
carcinoma yield was obtained even when TPA promo-
tion in stage II was omitted (data not shown). Thus,
MNNG is not useful as a stage III agent when given
for30weeks. Fewerexposures toMNNG, over aperiod
from 1 to 10 weeks, are currently beingtested for stage
III activity.
Malignant Conversion in Charles River
CD-1 Mice
To verify the three-stage carcinogenesis results in
mice other than SENCARs, a similar experiment was
performed with Charles River CD-1 mice. In CD-1 mice
initiated with DMBA (stage I) and promoted with TPA
for 12weeks (stage II), manypapillomasregressed after
TPA exposure was terminated (Fig. 2a). In the group
in which TPA was continued, the papilloma incidence
continued to rise until week 28. However, the final car-
cinoma yield was essentially equal in groups receiving
continuous TPA or acetone solvent alone in stage III
(Fig. 2b). Since the number ofpapillomas remaining at
the time carcinomas were first seen was markedly re-
duced in the acetone group, TPA-dependent papillomas
are at very low risk for carcinoma formation, whereas
persistent papillomas (those which remain after ter-
mination ofTPA treatment) are at high risk. The max-
imumpapilloma incidence at 16 weeks was reduced 30%
bytreatmentwith4-NQOinstageIII, butthepapilloma
regression rate was unaffected by urethane or 4-NQO
compared to that in acetone-treated mice (Fig. 2a).
Either4-NQO orurethane in stage III clearlyincreased
both the rate of carcinoma appearance and the final
carcinoma yield relative to TPA or acetone treatment
(Fig. 2b). The low carcinoma yield in control groups not
exposed to TPA in stage II confirms the requirement
for a papilloma stage priorto carcinoma formation (Fig.
3). Stage I initiation followed by solvent treatment in
stage II and urethane or 4-NQO in stage III produced
fewpapillomas (3 with urethane and 31 with 4-NQO per
40 mouse group) and almost no malignancies (Fig. 3).
However, repeated MNNG givento DMBA-initiated or
uninitiated CD-1 mice induced carcinomas in over half
ofthe mice (Fig. 4), as we observed in SENCAR mice.
The percent conversion of papillomas to carcinomas
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FIGURE 3. Carcinoma incidence in three-stage carcinogenesis in
CD-1 mice. In the experiment described in Figure 2, treatment
with TPA (@, A) is compared to treatment with acetone (0, A)
in stage II.
was calculated at week 60 based on the maximum num-
ber of papillomas that developed in each group shown
in Figure 2. With continued TPA treatment, a 2.5%
malignant conversion rate wasfound, compared to 3.7%
in the acetone control group. The final percent conver-
sion was increased to 5.5% with urethane and to 7.9%
with 4-NQO. These percentages are approximately
twice those calculated in SENCAR mice (5) since the
papilloma incidence is about half that found in SEN-
CARs and the carcinoma incidence is comparable. The
difference between mice treated with acetone or TPA
and mice treated with genotoxic agents in stage III was
much more striking at earlier times. At 40 weeks, the
percent conversion was 0.75% with acetone, 1.2% with
TPA, 4.2% with urethane and 6.3% with 4-NQO. Thus,
genotoxic agents in stage III appear to increase the
number of carcinomas and also to accelerate their for-
mation.
Malignant Conversion in SENCAR
or CD-1 Mice Treated with TPA in
Stage Ill
In contrast to CD-1 mice, continued TPA treatment
of initiated SENCAR mice after an optimal course of
TPAtreatment did not result in amaintenance ofahigh
papilloma incidence (Fig. 5). Papillomas regressed
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FIGURE 4. Carcinoma incidence in CD-i mice treated with MNNG
in stage III. Mice were treated with DMBA (0, A) or acetone (U)
solvent in stage I. In stage II, mice received either TPA (10 ,ug/
0.2 mL acetone once weekly for 12 weeks) (0) or 0.2 mL acetone
once weekly for 12 weeks (A, U). All three groups were treated
with MNNG (120 ,ug/0.2 mL acetone) in stage III.
whether mice were exposed to continued TPA or ace-
tone solvent. The mechanism responsible for this ap-
parent absence of TPA-dependent papillomas in SEN-
CAR mice is unclear. As with CD-1 mice, however, the
final carcinomayield was the same withTPA orsolvent,
although the latent period may be somewhat shorter in
the continuous TPA group.
Metastasis of Squamous Cell
Carcinomas
In the three-stage carcinogenesis experiment in CD-
1 mice described in Figures 2-4, complete autopsies
were performed on all animals and possible metastatic
lesions were examined histologically. After DMBA ini-
tiation, 12weeksofTPApromotionandeithercontinued
TPA oracetone treatment forafurther40weeks, about
20% of the mice with 1 or more carcinomas also devel-
oped metastatic carcinomas (Table 2). With MNNG in
stage III, the overall metastasis rate increased to 30%,
but with 4-NQO, a metastasis rate of only 15% was
found. With acetone, TPA, MNNG, or 4-NQO, a total
of 14 metastases were seen in lymph nodes with only 4
in the lungs. Both the pattern and frequency ofmetas-
tasis were altered in the mice exposed to urethane.
Metastases were seen in one-third of the carcinoma-
bearing mice, with three in lymph nodes and six in
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FIGURE 5. Papilloma and carcinoma incidence in papilloma-bearing
mice treated with TPA or acetone solvent: comparison of CD-1
and SENCAR mice. Charles River CD-1 mice were initiated with
50 ,ug DMBA and promoted with 12 weekly applications of 10lg
TPA. Beginning at week 13, mice were treated once per week
with either (A) 0.2 mL acetone or (O) 10 jigTPA/0.2 mL acetone.
Similarly, papillomas were induced in SENCAR mice by initiation
with 20 ,ug DMBA and promotion by 10 weekly applications of2.5
,ug TPA. Beginning at week 11, mice were treated weekly with
either (A) 0.2 mL acetone or (0) 2.5 ,ug TPA/0.2 mL acetone.
lungs. The lung squamous cell carcinomas seen after
stage III urethane exposure were not primary, ure-
thane-induced lesions since identical urethane treat-
ment of uninitiated mice or initiated mice not treated
with TPA in stage II produced no squamous cell car-
cinomas of the skin or lung. Primary lung adenomas
wereobserved inabouthalfthemiceinthesetwogroups
as well as in the group that developed metastatic lung
tumors.
The overall rate ofmetastasis appeared to be slightly
lower in SENCAR mice treated in stage III with ace-
tone (Table 2). A group treated with TPA in stage III
was not included in this experiment, so no data are
Table 2. Frequency and distribution of metastases in mice
bearing skin squamous cell carcinomas.
% of carcinoma-bearing mice with metastasesa
Total (one or
Stage III more sites) Lymph node Lung
treatment CD-1 SENCAR CD-1 SENCAR CD-1 SENCAR
Acetone 16.7 11.1 16.7 5.6 11.1 11.1
TPA 23.1 23.1 0 -
MNNG 30.0 26.3 25.0 15.8 5.0 15.8
Urethane 33.3 11.1 12.5 0 25.0 11.1
4-NQO 15.0 19.0 15.0 9.5 5.0 9.5
aGroups of40 female CD-1 mice were initiated with 50 ,ug DMBA
(stage I) and promoted with 12 weekly applications of 10 ,ug TPA
(stage II). In SENCAR mice, groups of30 females were initiated by
20 ,ug DMBA and promoted with 10weekly applications of2 ,gTPA.
The indicated stage III treatments once weekly from weeks 13 to 52
in CD-1 mice and weeks 11 to 40 in SENCAR mice were as follows:
acetone, 0.2 mL; TPA, 10 ,ug; MNNG, 120 ,ug; urethane, 20 mg IP;
4-NQO, 250 ,ug. Some animals developed metastases in both lymph
nodes and lungs. Between 13 and 24 carcinoma-bearing mice were
examined in each group. Squamous cell carcinomas in the lungs or
lymph nodes were observed only in mice that bore skin squamous cell
carcinomas.
presented on metastases in SENCAR mice treated
long-term with TPA. In contrast to CD-1 mice, stage
III exposure to urethane did not affect the number of
mice with lung metastases. Although 4-NQO increased
the metastatic rate only slightly, MNNG in stage III
more than doubled the overall rate of metastasis.
These studies were performed under NCI Contract NO1-CP-41015
awarded to Microbiological Associates, Bethesda, MD 20816. The
work described in this paper was not funded by EPA and no official
endorsementshouldbeinferred. WethankMaxineBellmanandSandy
White for secretarial assistance.
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